Targeting mitogen-activated protein kinase in acute ischaemic stroke

Despite the substantial progress that has been made over the past decades, there remains a dearth of approaches for the effective management of acute stroke. To date, many attempts for brain protection fail in clinical trials, presenting an unmet need for identification of new treatment options. This article is protected by copyright. All rights reserved.